课题基金 / 基金详情

Increasing PKG activity protects aging kidney from ischemic-reperfusion induced injury

Increasing PKG activity protects aging kidney from ischemic-reperfusion induced injury
增加 PKG 活性可保护衰老肾脏免受缺血再灌注引起的损伤
批准号:
8821772
负责人:
Shuxia Wang
金额:
$7.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-03-01 至 2017-02-28

项目摘要

项目成果

Shuxia Wang的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Aging is associated with increased incidence of acute kidney injury (AKI). This age-dependent increase in susceptibility to AKI is linked to a decreased renal functional recovery and even progression to advanced chronic kidney disease, a severe health problem worldwide. Despite advances in our understanding of the cellular and molecular aspects of AKI in recent years, the relationship between aging and AKI remains poorly understood and requires further mechanistic studies. Preliminary studies demonstrated that nitric oxide (NO) and its downstream signaling pathway cGMP and cGMP-dependent protein kinase (PKG) was down-regulated in aging kidney, which was associated with aging-related renal functional changes. Moreover, preliminary data identified a novel inhibitory effect of PKG on tubular cell necrosis and apoptosis following renal ischemia reperfusion (IR) induced AKI in young mice and an inhibitory effect of PKG on macrophage migration, suggesting a therapeutic potential of PKG for renal IR injury. In this proposal, we will test the hypothesis that down-regulation of NO/cGMP/PKG signaling in the kidney contributes to increased susceptibility to ischemia reperfusion-mediated AKI in older individuals. We will determine whether genetically or pharmacologically increased PKG activity reduces the susceptibility of old animals to ischemia mediated AKI in Aim 1. The mechanisms of reduced NO/cGMP/PKG signaling in aging kidney will be determined in Aim 2. These studies will establish the significance of PKG in acute kidney injury in aging population. Importantly, we will test a novel potential application of sildenafil fr AKI in older population. Sildenafil is an inhibitor of cGMP specific phosphodiesterase 5 (PDE5) and a FDA approved drug for treatment of pulmonary hypertension and erectile dysfunction. Hopefully, these proposed studies will lead to new therapeutic strategy for acute kidney injury in aging population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease
  • 批准号:
    10538925
  • 项目类别:
  • 资助金额:
    $49.14万
  • 财政年份:
    2022
  • 负责人:
    Shuxia Wang
  • 依托单位:
Role of SMPDL3B in obesity-associated non-alcoholic fatty liver disease
  • 批准号:
    10653240
  • 项目类别:
  • 资助金额:
    $47.82万
  • 财政年份:
    2022
  • 负责人:
    Shuxia Wang
  • 依托单位:
CD47 as a therapeutic target for obesity
CD47 as a therapeutic target for obesity
海外基金